Roger Hajjar

Company: Sardocor Corp

Job title: President

Seminars:

Elucidating Novel AAV/SERCA2a Gene Therapy for the Treatment of Duchenne Cardiomyopathy 9:30 am

Cardiomyopathy associated with Duchenne continues to cause morbidity and mortality in affected patients Directed gene therapy to treat cardiomyopathy has not been available yet Delivery of AAV/SERCA2a in patients with cardiomyopathy is a promising strategy for improving the lives of patients in needRead more

day: Conference Day 1